Metoprolol group (n=19) | Celiprolol group (n=21) | Placebo group (n=10) | p value | |
---|---|---|---|---|
Age (years) | 56.1 (2.8)* † | 67.1 (2.1)* § | 61 (2.9)† § | * 0.008,† 0.28, § 0.11 |
Range | 20 to 72 | 45 to 82 | 47 to 76 | |
Sex | ||||
Male | 16 | 13 | 9 | |
Female | 3 | 8 | 1 | |
Aetiology | ||||
IDC | 10 | 8 | 2 | |
ICM | 7 | 10 | 5 | |
HTHD | 2 | 3 | 3 | |
NYHA functional class | ||||
II | 8 | 9 | 5 | |
III | 11 | 10 | 5 | |
IV | 0 | 2 | 0 | |
Mean NYHA class | 2.6 (0.12) | 2.7 (0.15) | 2.5 (0.18) | 0.65 |
Symptom questionnaire score | 18.1 (3.5) | 13.5 (2.7) | 7.7 (2.9) | 0.12 |
ETT (6 min walk, feet) | 1246 (54) | 1191 (55) | 1304 (69) | 0.47 |
Baseline blood pressure (mm Hg) | ||||
Sitting | 114(5)/70(3) | 113(4)/71(2) | 105(6)/65(3) | 0.48/0.35 |
Standing | 119(6)/76(3) | 114(4)/74(2) | 107(6)/68(4) | 0.37/0.2 |
Heart rate (beats/min) | 79.3 (2.5) | 77.9 (2.8) | 79.5 (3.5) | 0.91 |
LVEF (%) | 26.9 (3.1) | 30.2 (2.7) | 33.1 (4.0) | 0.42 |
LVEDD (cm) | 7.2 (0.3) | 6.9 (0.3) | 6.7 (0.2) | 0.55 |
FS (%) | 14.4 (1.3) | 15 (1.1) | 18 (1.5) | 0.19 |
ANF (pg/ml) | 141.4 (32.9) | 193.4 (73.5) | 269.4 (187.7) | 0.64 |
BNP (pg/ml) | 151.9 (22.8) | 166.4 (36.1) | 128.3 (24.8) | 0.73 |
Treatment | ||||
Frusemide dose (mg) | 85.3 (12.7) | 56.5 (8.6) | 66 (13) | 0.16 |
ACEI (% receiving) | 16 (84%) | 15 (71%) | 10 (100%) | |
Nitrates (% receiving) | 10 (53%) | 14 (67%) | 3 (30%) |
Values are means (SEM) unless otherwise stated.
ACEI, angiotensin converting enzyme inhibitors; ANF, atrial natriuretic factor; BNP, brain (ventricular) natriuretic peptide; ETT, exercise tolerance test; FS, fractional shortening; HTHD, hypertensive heart disease; ICM, ischaemic cardiomyopathy; IDC, idiopathic dilated cardiomyopathy; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.